title: Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.
abstract: Brentuximab vedotin (BV) is approved for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma, and relapsed or refractory systemic anaplastic large-cell lymphoma. Several uncertainties remain regarding the optimal use of the drug in its approved indications as well as outside them. This article reports recommendations on the use of BV issued during a consensus project, sponsored by the Italian Society of Hematology (SIE) and its affiliate societies, Società Italiana di Ematologia Sperimentale (SIES) and Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Scientific evidence on BV was evaluated by a panel of experts, and consensus was developed by group discussion for key questions selected according to the clinical relevance. The following key issues were addressed: testing CD30 positivity to assess eligibility to BV; assessing practice indications of BV in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma; providing pretreatment evaluation of patients candidates to BV; monitoring the response to BV; managing patients treated with BV; and assessing the role of BV in other CD30-positive lymphomas.
authors.affiliation: Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: Division of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milan, Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Corradini
authors.affiliation: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
authors.forename: Alessandro M
authors.initials: AM
authors.lastname: Gianni
authors.affiliation: Department of Diagnostic, Clinical and Public Health Medicine, Modena Cancer Center, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Federico
authors.affiliation: Department of Medical Oncology and Hematology, IRCCS Humanitas Cancer Center, Rozzano, Milano, Italy.
authors.forename: Armando
authors.initials: A
authors.lastname: Santoro
authors.affiliation: Department of Oncology and Hematology, "Città della Salute e della Scienza" University-Hospital, Torino, Italy.
authors.forename: Umberto
authors.initials: U
authors.lastname: Vitolo
authors.affiliation: Center of the Study of Myelofibrosis Biotechnology Research Area, IRCCS Policlinico S Matteo Foundation, Pavia, Italy. Electronic address: barosig@smattteo.pv.it.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Barosi
authors.affiliation: University of Bologna, Bologna, Italy.
authors.forename: Sante
authors.initials: S
authors.lastname: Tura
mesh_terms: D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D007558:Italy; D017730:Ki-1 Antigen / Q000378:metabolism*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
keywords: Brentuximab vedotin; Consensus project; Guidelines; Hodgkin lymphoma; Systemic anaplastic large-cell lymphoma